| 联合缬沙坦用药治疗乙型肝炎肝纤维化的成本—效果分析 |
| |
| 引用本文： | 朱凌云,许岭,童宁,俞斐,马力.联合缬沙坦用药治疗乙型肝炎肝纤维化的成本—效果分析[J].中国药事,2017,31(3):258-262. |
| |
| 作者姓名： | 朱凌云 许岭 童宁 俞斐 马力 |
| |
| 作者单位： | 东南大学附属第二医院, 南京 210003,东南大学附属第二医院, 南京 210003,东南大学附属第二医院, 南京 210003,东南大学附属第二医院, 南京 210003,东南大学附属第二医院, 南京 210003 |
| |
| 基金项目： | 南京市科技发展基金临床药学基金资助项目（编号2012YX014） |
| |
| 摘 要： | 目的：评价两种治疗慢性乙型肝炎肝纤维化方案的成本-效果。方法：90例乙型肝炎肝纤维化患者随机分为恩替卡韦加复方鳖甲软肝组（A组）和恩替卡韦加复方鳖甲软肝片联合缬沙坦组（B组），疗程6个月。分别在治疗前后检测两组患者的肝纤维化指标、瞬时弹性成像，计算有效率，比较两种方案的成本-效果。结果：A组成本为9232.50元，有效率为78.26%，成本-效果比为11797；B组成本为9527.70元，有效率为86.36%，成本-效果比为11031，B组方案具有较好的成本-效果。结论：恩替卡韦加复方鳖甲软肝联合缬沙坦组治疗慢性乙肝肝纤维化优于恩替卡韦加复方鳖甲软肝片组。
|
| 关 键 词： | 缬沙坦 乙型肝炎肝纤维化 成本-效果分析 |
| 收稿时间： | 2016/6/17 0:00:00 |
Cost-effectiveness Analysis of Combined Valsartan Medication in the Treatment of Chronic Hepatitis B Fibrosis |
| |
| Zhu Lingyun,Xu Ling,Tong Ning,Yu Fei and Ma Li.Cost-effectiveness Analysis of Combined Valsartan Medication in the Treatment of Chronic Hepatitis B Fibrosis[J].Chinese Pharmaceutical Affairs,2017,31(3):258-262. |
| |
| Authors: | Zhu Lingyun Xu Ling Tong Ning Yu Fei and Ma Li |
| |
| Institution: | The Second Affiliated Hospital of Southeast University, Nanjing 210003, China,The Second Affiliated Hospital of Southeast University, Nanjing 210003, China,The Second Affiliated Hospital of Southeast University, Nanjing 210003, China,The Second Affiliated Hospital of Southeast University, Nanjing 210003, China and The Second Affiliated Hospital of Southeast University, Nanjing 210003, China |
| |
| Abstract: | Objective: To analyze the cost-effectiveness of two medication schemes in the treatment of chronic hepatitis B fibrosis. Methods: 90 cases of chronic hepatitis B fibrosis were randomly divided into entecavir Fufang Biejia Ruangan tablets group (group A, n=46) and entecavir Fufang Biejia Ruangan tablets combined with Valsartan group (group B, n=34). The liver fibrosis index and transient elastography of 2 groups were detected before and after 6-month-treatment, and effective rate was calculated to compare the cost-effectiveness of the 2 groups. Results: The cost, effective rate and cost-effectiveness ratio of group A were 9232.50 yuan, 78.26% and 11797 respectively; those of group B were 9527.70 yuan, 86.36% and 11031 respectively; indicating group B had better cost-effectiveness. Conclusion: The cost-effectiveness of entecavir and Fufang Biejia Ruangan tablets combined with Valsartan is better than that of entecavir and Fufang Biejia Ruangan tablets in the treatment of chronic hepatitis B fibrosis. |
| |
| Keywords: | valsartan chronic hepatitis B fibrosis cost-effectiveness analysis |
|
| 点击此处可从《中国药事》浏览原始摘要信息 |
| 点击此处可从《中国药事》下载免费的PDF全文 |
|
